TWEAK Protein (AA 97-249)

Produktnummer ABIN2666449

Produktdetails

Target: TWEAK (TNFSF12) (Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Proteineigenschaft: AA 97-249

Spezies: Human

Quelle: Escherichia coli (E. coli)

Applikation: Biochemical Assay (BCA)

Reinheit: > 98 % , as determined by Coomassie stained SDS-PAGE.

Endotoxin-Niveau:

Less than 0.1 ng per μg of protein.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Kommentare:

Biological activity: ED50 < 10 ng/ml, corresponding to a specific activity of > 1 x 107 units/mg, as determined by the dose dependent stimulation of production of IL-8 by human PBMC.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: For maximum results, quick spin vial prior to opening. Reconstitute in 10 mM sodium phosphate, pH 7.5 to a concentration of 1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer containing a carrier protein such as 0.1 % BSA and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized

Handhabung: Avoid repeated freeze/thaw cycles.

Lagerung: -20 °C

Informationen zur Lagerung: Unopened vial can be stored at -20°C or -70°C.

Antigendetails

Target: TWEAK (TNFSF12) (Tumor Necrosis Factor (Ligand) Superfamily, Member 12 (TNFSF12))

Andere Bezeichnung: TWEAK (TNFSF12 Produkte)

Synonyme: APO3L Protein, DR3LG Protein, TWEAK Protein, Apo3l Protein, Dr3l Protein, Dr3lg Protein, Tweak Protein, TNF superfamily member 12 Protein, tumor necrosis factor (ligand) superfamily, member 12 Protein, TNFSF12 Protein, Tnfsf12 Protein

Hintergrund: TWEAK (TNFSF12) is a "TNF-like weak inducer" of apoptosis through a non-death domain-dependent mechanism. TWEAK is a type II membrane protein which exhibits a single internal hydrophobic domain of 27 amino acids in the N-terminal region. TWEAK is proteolytically cleaved to produce a soluble cytokine that signals as a trimerized molecule. Fibroblast growth factor-inducible 14 (Fn14)/TWEAKR has been described as a receptor for TWEAK, and it is associated with proliferation of endothelial cells and angiogenesis. However, TWEAK mediates signal transduction and linear differentiation of monocyte/macrophage cells lacking Fn14/TWEAKR, suggesting that such cells contain an alternative TWEAK receptor. Elevated levels of TWEAK and/or Fn14 have been found to be associated with the pathogenesis of rheumatoid arthritis, skeletal muscle wasting, systemic lupus erythematosus, multiple sclerosis, stroke, neuroinflammation and neurodegeneration, and several types of cancer. The pathological functions of TWEAK are primarily attributed to its ability to induce the expression of several proinflammatory cytokines, chemokines, cell adhesion molecules, and matrix-degrading enzymes mainly through the activation of NF-κB, a major proinflammatory transcription factor. It has been described that CD163 (a scavenger receptor) might be acting as a receptor decoy for the ligand TWEAK.

Molekulargewicht: The 154 amino acid N-terminal methionylated recombinant protein has a predicted molecular mass of 17 kDa.

Pathways: Apoptose